Clinical Trial Update: Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing closed therapy of FF/UMEC/VI versus open therapy FF/VI with UMEC in COPD; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Furoate/Umclidinium Bromide/Vilanterol
• Fluticasone Furoate/Vilanterol (fluticasone furoate/vilanterol)
• Umclidinium Bromide (umeclidinium bromide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2019-07-15